{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:25:26Z","timestamp":1781951126607,"version":"3.54.5"},"reference-count":26,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0721","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:10:22Z","timestamp":1776982222000},"page":"n\/a","source":"Crossref","is-referenced-by-count":1,"title":["Conversion Liver Resection for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Single Tremelimumab Regular Interval Durvalumab Regimen as a Second-Line Therapy: A Case Report"],"prefix":"10.70352","volume":"12","author":[{"given":"Diyar","family":"Akhmet","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-4300","authenticated-orcid":false,"given":"Akihiko","family":"Soyama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baglan","family":"Askeyev","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Okano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisamitsu","family":"Miyaaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Digestive Surgery and Transplantology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209\u201349.","DOI":"10.3322\/caac.21660"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Tan DJH, Tang ASP, Lim WH, et al. Survival trends in sorafenib for advanced hepatocellular carcinoma: a reconstructed individual patient data meta-analysis of randomized trials. Liver Cancer 2023; 12: 445\u201356.","DOI":"10.1159\/000529824"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382: 1894\u2013905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer 2021; 10: 539\u201344.","DOI":"10.1159\/000519749"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kudo M. Durvalumab plus tremelimumab: a novel combination immunotherapy for unresectable hepatocellular carcinoma. Liver Cancer 2022; 11: 87\u201393.","DOI":"10.1159\/000523702"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Mori H, Maehira H, Nitta N, et al. Conversion surgery following severe cytokine release syndrome induced by immune checkpoint inhibitors doublet in advanced hepatocellular carcinoma. Clin J Gastroenterol 2025; 18: 739\u201345.","DOI":"10.1007\/s12328-025-02155-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kawamura Y, Akuta N, Fujiyama S, et al. Two cases of advanced hepatocellular carcinoma who responded well to the combination of durvalumab plus tremelimumab after disease progression during atezolizumab plus bevacizumab therapy under bevacizumab withdrawal. Cureus 2023; 15: e45385.","DOI":"10.7759\/cureus.45385"},{"key":"8","unstructured":"8) Yamakado K, Takaki H. The new updated Barcelona clinic liver cancer staging system: roles of trans-arterial chemoembolization and homework to interventional radiologists. Interv Radiol (Higashimatsuyama) 2023; 10: e20220035."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Hwang SY, Lee SL, Liu H, et al. Second-line treatment after failure of immune checkpoint inhibitors in hepatocellular carcinoma: tyrosine kinase inhibitor, retrial of immunotherapy, or locoregional therapy? Liver Cancer 2023; 13: 246\u201355.","DOI":"10.1159\/000534303"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) \u00d6cal O, Schinner R, Sch\u00fctte K, et al. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging 2022; 22: 1.","DOI":"10.1186\/s40644-021-00439-x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tian X, Yan T, Liu F, et al. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights. Front Pharmacol 2022; 13: 991052.","DOI":"10.3389\/fphar.2022.991052"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lee MMP, Chan LL, Chan SL. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. J Liver Cancer 2023; 23: 262\u201371.","DOI":"10.17998\/jlc.2023.07.17"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Scheiner B, Roessler D, Phen S, et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep 2022; 5: 100620.","DOI":"10.1016\/j.jhepr.2022.100620"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Miura R, Ono A, Yano S, et al. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma. Medicine (Baltimore) 2024; 103: e39289.","DOI":"10.1097\/MD.0000000000039289"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Adhikari S, Doolin J. Rechallenging unresectable hepatocellular carcinoma with the STRIDE regimen: a case report of significant AFP response after atezolizumab-bevacizumab intolerance. Case Rep Oncol 2025; 18: 942\u20138.","DOI":"10.1159\/000546711"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Komatsu S, Fujishima Y, Kido M, et al. Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report. BMC Gastroenterol 2021; 21: 470.","DOI":"10.1186\/s12876-021-02053-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hidaka Y, Tomita M, Desaki R, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol 2022; 20: 228.","DOI":"10.1186\/s12957-022-02691-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tameda M, Tanaka H, Toyomasu Y, et al. Efficacy and safety of hypofractionated radiation therapy combined with immunotherapy for hepatocellular carcinoma with Vp4 portal vein tumor thrombosis. Hepatol Res 2026; 56: 246\u201352.","DOI":"10.1111\/hepr.70051"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Krishnamurthy N, Cherry D, Rodriguez-Russo C, et al. Concurrent radiation and immunotherapy for unresectable hepatocellular carcinoma with extensive portal vein tumor thrombus. Adv Radiat Oncol 2025; 10: 101856.","DOI":"10.1016\/j.adro.2025.101856"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kobayashi K, Ogasawara S, Takahashi A, et al. Evolution of survival impact of molecular target agents in patients with advanced hepatocellular carcinoma. Liver Cancer 2021; 11: 48\u201360.","DOI":"10.1159\/000519868"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Vigan\u00f2 M, La Milia M, Grassini MV, et al. Hepatotoxicity of small molecule protein kinase inhibitors for cancer. Cancers (Basel) 2023; 15: 1766.","DOI":"10.3390\/cancers15061766"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Rimassa L, Danesi R, Pressiani T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019; 77: 20\u20138.","DOI":"10.1016\/j.ctrv.2019.05.004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Sangro B, Chan SL, Kelley RK, et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol 2024; 35: 448\u201357.","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Fujii Y, Kawaoka T, Shirane Y, et al. First-line durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in real-world clinical practice. Oncology 2025; 103: 742\u2013747.","DOI":"10.1159\/000542517"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Brunelli A, Mariolo A, Aigner C, et al. Surgical results after neoadjuvant nivolumab and platinum-based chemotherapy for resectable lung cancer. A multicentre European real clinical practice analysis. Eur J Cardiothorac Surg 2025; 67: ezaf343.","DOI":"10.1093\/ejcts\/ezaf343"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0721\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:43:02Z","timestamp":1777092182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0721\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0721","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0721"}}